# Endocrine Agents: Diabetes – Non-Insulin

## Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication within the same class not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindication to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Non-Preferred

1.  There must have been a therapeutic failure of at least 60-day trial and failure with three preferred products

    Note: Inadequate clinical response after at least 60 days of recommended therapeutic dose with documented adherence to the regimen.

### Diabetes - Oral Hypoglycemics, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor And DPP-4 Combinations

| **Preferred**                                                                 | **Non-Preferred**                      |
|-------------------------------------------------------------------------------|----------------------------------------|
| No less than **90 days** of at least **one** preferred DPP-4 and SGLT product | GLYXAMBI (empagliflozin/ linagliptin)  |
|                                                                               | QTERN (dapaglifozin-saxagliptin)       |
|                                                                               | STEGLUJAN™ (ertugliflozin/sitagliptin) |

Soliqua and Xultophy Request must address inability to use the individual components.

## Formulary

Endocrine Agents: Diabetes – Non-Insulin

| PREFERRED                               | NON-PREFERRED                      |
|-----------------------------------------|------------------------------------|
| Acarbose                                | Adlyxin                            |
| Actoplus Met XR                         | Alogliptin                         |
| Byetta                                  | Alogliptin/Metformin               |
| Farxiga                                 | Bydureon Bcise                     |
| Glimepiride                             | Glimepiride/Pioglitazone           |
| Glipizide                               | Glucophage                         |
| Glipizide/Metformin                     | Glyxambi                           |
| Glyburide                               | Invokamet XR                       |
| Glyburide/Metformin                     | Jentadueto XR                      |
| Invokamet                               | Kombiglyze XR                      |
| Invokana                                | Metformin ER (Generic of Fortamet) |
| Janumet                                 | Metformin Sol                      |
| Janumet XR                              | Onglyza                            |
| Januvia                                 | Ozempic                            |
| Jardiance                               | Pioglitazone/Alogliptin            |
| Jentadueto                              | Qtern                              |
| Metformin                               | Rybelsus                           |
| Metformin ER (Generic of Glucophage XR) | Segluromet                         |
| Miglitol                                | Soliqua                            |
| Nateglinide                             | Steglatro                          |
| Pioglitazone                            | Steglujan                          |
| Pioglitazone/Metformin                  | Symlinpen                          |
| Repaglinide                             | Synjardy XR                        |
| Repaglinide/Metformin                   | Trijardy XR                        |
| Synjardy                                | Xigduo XR                          |
| Tradjenta                               | Xultophy                           |
| Trulicity                               |                                    |
| Victoza                                 |                                    |

### Link to Criteria

[Endocrine Agents: Diabetes - Non-Insulin](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=49)
